Saturday 17 October 2026
Export EPRX’s income statement to Excel — free account
Eupraxia Pharmaceuticals Inc.
EPRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 11.5% and free cash flow fell 56.4%, each against the same quarter a year earlier.
6.62
0.15
−2.22%
Follow EPRX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 2.20 | 2.68 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 4.08 | 8.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 29 | 33 | 49 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | (19) | (29) | (26) | (39) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | (19) | (29) | (26) | (39) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (0.98) | (1.17) | (0.76) | (1.03) | |||||
| Cash flow | — | — | — | — | — | — | (0.75) | (0.86) | (0.88) | (0.71) | |||||
| Capex | — | — | — | — | — | — | (0.01) | 0.00 | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | (0.76) | (0.86) | (0.89) | (0.73) | |||||
| Book value | — | — | — | — | — | — | 0.37 | 0.04 | 0.94 | 2.01 | |||||
| Shares, m | — | — | — | — | — | — | 19 | 24 | 34 | 40 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (14) | (21) | (30) | (29) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | (1) | |||||
| Free cash flow | — | — | — | — | — | — | (15) | (21) | (30) | (29) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 16 | 0 | 31 | 79 | ||||
| Total debt | — | — | — | — | — | — | 9 | 10 | — | 0 | |||||
| Net debt | — | — | — | — | — | — | (9) | (9) | (33) | (80) | |||||
| Shareholders’ equity | — | — | — | — | — | — | 7 | 1 | 32 | 80 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (143.29) | (93.93) | (67.89) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | (696.79) | (5,054.21) | (161.71) | |||||
Negative figures in brackets.
Charts ten years each
Eupraxia Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALT Altimmune, Inc. | $459.1M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| AUTL Autolus Therapeutics PLC Sponsored ADR | $457.8M | — (loss-making) | — (loss-making) | +118.37% (above 0%: growing) | n/m | +67.55% (above 0%: growing) | 55.20% | (95.95%) | Compare |
| OCS Oculis Holding AG | $456.8M | — (loss-making) | — (loss-making) | +23.96% (above 0%: growing) | n/m | −10.40% (below 0%: shrinking) | 100.00% | (7,603.42%) | Compare |
| EPRX Eupraxia Pharmaceuticals Inc. | $446.2M | — (loss-making) | — | — | n/m | −56.41% (below 0%: shrinking) | — | 0.00% | |
| MPLT MapLight Therapeutics, Inc. | $445.7M | — (loss-making) | — | — | n/m | −31.91% (below 0%: shrinking) | — | 0.00% | Compare |
| OVID Ovid Therapeutics | $441.4M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| PROK ProKidney Corp. | $439.9M | — (loss-making) | — (loss-making) | −32.13% (below 0%: shrinking) | n/m | −28.03% (below 0%: shrinking) | 100.00% | (32,248.67%) | Compare |
| INDP Indaptus Therapeutics, Inc. | $437.7M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PRTA Prothena Corporation plc | $436.4M | — (loss-making) | 188× | −77.15% (below 0%: shrinking) | n/m | +44.64% (above 0%: growing) | 100.00% | (2,089.21%) | Compare |
| Median of peers | $443.5M | — | — | +71.17% | — | −17.83% | 100.00% | (1,092.58%) |
Eupraxia Pharmaceuticals Inc. (EPRX) key facts
- Eupraxia Pharmaceuticals Inc. (EPRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, EPRX traded at $6.62, a market capitalization of $446.2 million.
- Return on equity was −161.7% and debt-to-equity 0.01.
Eupraxia Pharmaceuticals Inc. (EPRX) Latest News
No news at this impact. Lower the threshold for more.